Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.
Waltham, Massachusetts-based biotech firm Skyhawk Therapeutics is expanding a strategic collaboration deal with Merck as the two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.
Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.
PerkinElmer Inc. announced that it has entered into a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN.
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. today announced that it has entered into a collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal […]
LONDON— GlaxoSmithKline GSK -3.47 % PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis AG NVS -3.07 % for […]
